-

Johnson & Johnson to Participate in the 2024 Wells Fargo Healthcare Conference

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the 2024 Wells Fargo Healthcare Conference on Thursday, September 5th, at the Encore Boston Harbor, Evertte, MA. Tim Schmid, Executive Vice President, WorldWide Chairman, MedTech will represent the Company in a session scheduled at 11:00 am (Eastern Time).

This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.

The audio webcast replay will be available approximately 48-hrs after the webcast.

Contacts

Media contact:
media-relations@its.jnj.com

Investor contact:
investor-relations@its.jnj.com

Industry:

Johnson & Johnson

NYSE:JNJ
Release Versions
English

Contacts

Media contact:
media-relations@its.jnj.com

Investor contact:
investor-relations@its.jnj.com

More News From Johnson & Johnson

Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced with TIME the launch of the Healthcare Champion of the Year. The new branded recognition will honor healthcare professionals in the U.S., selected by Johnson & Johnson and a panel of industry experts, whose care, innovation and grit are driving health system change to advance better care for all. Nominations for the inaugural TIME Healthcare Champion of the Year, in partnership with Johnson & Johnson...

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2026 of $1.34 per share on the company’s common stock. The dividend is payable on September 8, 2026 to shareholders of record at the close of business on August 25, 2026. The ex-dividend date is August 25, 2026. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare inn...

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2026. “Johnson & Johnson delivered strong second-quarter results, demonstrating the power of our innovation, the depth of our portfolio and the momentum in our pipeline as we advance transformative treatments that address the world’s toughest health challenges,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “With raised guidance and quarterly...
Back to Newsroom